These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26467069)

  • 1. Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination?
    Peluso I; Palmery M; Serafini M
    Curr Drug Metab; 2015; 16(9):833-46. PubMed ID: 26467069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific considerations on the prescription and therapeutic interchange of statins].
    García-Sabina A; Gulín-Dávila J; Sempere-Serrano P; González-Juanatey C; Martínez-Pacheco R
    Farm Hosp; 2012; 36(2):97-108. PubMed ID: 21820929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.
    Catapano AL
    Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis on the therapeutic equivalence of statins.
    Weng TC; Yang YH; Lin SJ; Tai SH
    J Clin Pharm Ther; 2010 Apr; 35(2):139-51. PubMed ID: 20456733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interactions with statins.
    Causevic-Ramosevac A; Semiz S
    Acta Pharm; 2013 Sep; 63(3):277-93. PubMed ID: 24152892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What you need to know about statins. Statins are the most commonly-prescribed drug and have revolutionized heart health.
    Heart Advis; 2009 Apr; 12(4):6-7. PubMed ID: 20387254
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.
    Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2014 Jan; 10(1):51-65. PubMed ID: 24156555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin-drug interactions: not a class effect.
    Frishman WH; Horn J
    Cardiol Rev; 2008; 16(4):205-12. PubMed ID: 18562811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of hypercholesterolemia with statins].
    Erikssen J; Madsen S
    Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3216-20. PubMed ID: 9411860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared].
    Kostner KM; Kostner GM
    Wien Klin Wochenschr; 1998 Oct; 110(18):625-30. PubMed ID: 9816634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-drug interactions that interfere with statin metabolism.
    Hirota T; Ieiri I
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis.
    Zechner J; Britza SM; Farrington R; Byard RW; Musgrave IF
    Life Sci; 2022 Feb; 291():119975. PubMed ID: 34560084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins.
    Vaquero MP; Sánchez Muniz FJ; Jiménez Redondo S; Prats Oliván P; Higueras FJ; Bastida S
    Nutr Hosp; 2010; 25(2):193-206. PubMed ID: 20449528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions of the statins and consequences for drug selection.
    Böger RH
    Int J Clin Pharmacol Ther; 2001 Sep; 39(9):369-82. PubMed ID: 11563683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.